Journal of bodywork and movement therapies · 2025
Can multicomponent aquatic training improve bradykinesia in individuals with Parkinson's disease? A quasi-experimental study with 4-week follow-up.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siega J, Leveck G C, Christinelli T, Doliny A E F, Paladini L H, Israel V L
Аннотация
OBJECTIVE: To investigate the effects of a 12-week Multicomponent Aquatic Training (MAT) program on bradykinesia in individuals with Parkinson's disease (PD).
METHODS: A quasi-experimental single-group study with repeated measures and convenience sampling was conducted. Assessments were performed at baseline (after a 4-week pre-study observation), pre- and post-12-week intervention, and at 4-week follow-up. The MDS-UPDRS bradykinesia subscale (BRAD), and the bradykinesia-akinesia incoordination test for kinesia (BRAIN KS) and akinesia (BRAIN AT) scores were used. The 10-m walk test was used to determine habitual (WS) and maximum (WSMAX) walking speed, and the 5 times sit-to-stand test (FTSST) to assess power, dynamic strength, and muscular endurance. Statistical analysis was performed using SPSS 20.0, and a significance level of p < 0.05 was adopted for significant differences. Data normality was assessed using the Shapiro-Wilk test. To verify the treatment effect, the Friedman non-parametric test was conducted, followed by the MSD multiple comparison test. Effect Size (ES) analysis was also conducted.
RESULTS: Twenty-eight individuals with PD between stages 1-3 in the Hoehn and Yahr Scale completed the study. Following MAT there were increases in BRAD (p < 0.001) with moderate ES (0.330), BRAIN KS on the side contralateral to the onset of the disease (p = 0.003) with small ES (0.165), WS and WSMAX (<0.001; p < 0.001), with large ES (0.565 and 0.565, respectively) and FTSST (p < 0.001) with moderate ES (0.448). All variables had a loss to follow-up, suggesting that improvements in follow-up were not maintained.
CONCLUSION: MAT improved bradykinesia and functional performance in individuals with PD. However, benefits diminished after follow-up, highlighting the importance of ongoing treatment to sustain and enhance outcomes.
METHODS: A quasi-experimental single-group study with repeated measures and convenience sampling was conducted. Assessments were performed at baseline (after a 4-week pre-study observation), pre- and post-12-week intervention, and at 4-week follow-up. The MDS-UPDRS bradykinesia subscale (BRAD), and the bradykinesia-akinesia incoordination test for kinesia (BRAIN KS) and akinesia (BRAIN AT) scores were used. The 10-m walk test was used to determine habitual (WS) and maximum (WSMAX) walking speed, and the 5 times sit-to-stand test (FTSST) to assess power, dynamic strength, and muscular endurance. Statistical analysis was performed using SPSS 20.0, and a significance level of p < 0.05 was adopted for significant differences. Data normality was assessed using the Shapiro-Wilk test. To verify the treatment effect, the Friedman non-parametric test was conducted, followed by the MSD multiple comparison test. Effect Size (ES) analysis was also conducted.
RESULTS: Twenty-eight individuals with PD between stages 1-3 in the Hoehn and Yahr Scale completed the study. Following MAT there were increases in BRAD (p < 0.001) with moderate ES (0.330), BRAIN KS on the side contralateral to the onset of the disease (p = 0.003) with small ES (0.165), WS and WSMAX (<0.001; p < 0.001), with large ES (0.565 and 0.565, respectively) and FTSST (p < 0.001) with moderate ES (0.448). All variables had a loss to follow-up, suggesting that improvements in follow-up were not maintained.
CONCLUSION: MAT improved bradykinesia and functional performance in individuals with PD. However, benefits diminished after follow-up, highlighting the importance of ongoing treatment to sustain and enhance outcomes.